FibroBiologics to Present at 2025 Cell & Gene Meeting on the Mesa
FibroBiologics (Nasdaq: FBLG), a clinical-stage biotechnology company with over 270 patents, announced its participation in the 2025 Cell & Gene Meeting on the Mesa Conference. Chief Scientific Officer Dr. Hamid Khoja will present on October 7, 2025, at 2:15 p.m. MST in Phoenix, Arizona.
The company, which specializes in developing therapeutics using fibroblasts and fibroblast-derived materials, plans to initiate a clinical trial for diabetic foot ulcers in Q1 2026. The presentation will provide updates on their fibroblast-based technologies and their potential applications in treating various chronic diseases.
FibroBiologics (Nasdaq: FBLG), una biotech clinicamente avanzata con oltre 270 brevetti, ha annunciato la sua partecipazione al 2025 Cell & Gene Meeting on the Mesa Conference. Il Chief Scientific Officer, il dottor Hamid Khoja, terrà una presentazione il 7 ottobre 2025 alle 14:15 MST a Phoenix, in Arizona.
L’azienda, specializzata nello sviluppo di terapie a base di fibroblasti e materiali derivati dai fibroblasti, prevede di avviare uno studio clinico per le ulcere del piede diabetico nel primo trimestre 2026. L'intervento presenterà aggiornamenti sulle tecnologie a base di fibroblasti e sui loro possibili impieghi nel trattamento di diverse malattie croniche.
FibroBiologics (Nasdaq: FBLG), una empresa de biotecnología en etapa clínica con más de 270 patentes, anunció su participación en la conferencia 2025 Cell & Gene Meeting on the Mesa. El director científico, el Dr. Hamid Khoja, presentará el 7 de octubre de 2025 a las 14:15 MST en Phoenix, Arizona.
La compañía, que se especializa en desarrollar terapias a partir de fibroblastos y materiales derivados de fibroblastos, tiene previsto iniciar un ensayo clínico para úlceras del pie diabético en el primer trimestre de 2026. La presentación proporcionará actualizaciones sobre sus tecnologías basadas en fibroblastos y sus posibles aplicaciones para tratar diversas enfermedades crónicas.
FibroBiologics (Nasdaq: FBLG)은 270건이 넘는 특허를 보유한 임상단계 생명공학 기업으로, 2025 Cell & Gene Meeting on the Mesa Conference에 참가한다는 소식을 발표했습니다. 최고과학책임자 Dr. Hamid Khoja는 2025년 10월 7일 오후 2시 15분 MST에 피닉스, 애리조나에서 발표합니다.
fibroblast 및 fibroblast 유래 재료를 이용한 치료법 개발에 초점을 맞춘 이 회사는 2026년 1분기에 당뇨발 궤양을 대상으로 임상시험을 시작할 예정이며, 발표에서는 fibroblast 기반 기술과 만성 질환 치료에의 잠재적 응용에 대한 업데이트를 제공합니다.
FibroBiologics (Nasdaq : FBLG), une entreprise de biotechnologie en phase clinique avec plus de 270 brevets, a annoncé sa participation à la conférence 2025 Cell & Gene Meeting on the Mesa. Le directeur scientifique, le Dr Hamid Khoja, présentera le 7 octobre 2025 à 14 h 15 MST à Phoenix, Arizona.
L’entreprise, spécialisée dans le développement de thérapies à base de fibroblastes et de matériaux dérivés de fibroblastes, prévoit de lancer un essai clinique pour les ulcères du pied diabétique au premier trimestre 2026. La présentation fournira des mises à jour sur leurs technologies à base de fibroblastes et leurs applications potentielles dans le traitement de diverses maladies chroniques.
FibroBiologics (Nasdaq: FBLG), ein klinisch fortgeschrittenes Biotechnologieunternehmen mit über 270 Patenten, gab seine Teilnahme an der 2025 Cell & Gene Meeting on the Mesa Conference bekannt. Chief Scientific Officer Dr. Hamid Khoja wird am 7. Oktober 2025 um 14:15 MST in Phoenix, Arizona, eine Präsentation halten.
Das Unternehmen, das sich auf die Entwicklung von Therapeutika auf Basis von Fibroblasten und fibroblasten-abgeleiteten Materialien spezialisiert hat, plant, im ersten Quartal 2026 eine klinische Studie für diabetische Fußulkus zu starten. Die Präsentation wird Updates zu den fibroblast-basierten Technologien und deren potenziellen Anwendungen bei der Behandlung verschiedener chronischer Krankheiten liefern.
FibroBiologics (ناسداك: FBLG)، شركة تقنية حيوية في مرحلةClinical تمتلك أكثر من 270 براءة اختراع، أعلنت عن مشاركتها في مؤتمر 2025 Cell & Gene Meeting on the Mesa. سيقدم كبير الباحثين العلميين الدكتور حامد خوجة عرضه في 7 أكتوبر 2025 الساعة 2:15 ظهرًا بتوقيت MST في فينيكس، أريزونا.
الشركة، المتخصصة في تطوير العلاجات باستخدام الخلايا الليفية والمواد المستمدة منها، تخطط لبدء تجربة سريرية لقرح القدم المصابة بالسكري في الربع الأول من 2026. سيقدم العرض تحديثات حول تقنياتهم المستندة إلى الخلايا الليفية وإمكاناتها في علاج العديد من الأمراض المزمنة.
FibroBiologics (纳斯达克：FBLG)，一家处于临床阶段的生物技术公司，拥有超过270项专利，宣布将参与 2025年 Mesa 会议的 Cell & Gene Meeting on the Mesa。首席科学官 Hamid Khoja 博士将于 2025年10月7日 太平洋夏令时下午2:15 在亚利桑那州凤凰城进行演讲。
该公司专注于利用成纤维细胞及其衍生材料开发治疗方法，计划在 2026年第一季度 启动糖尿病足溃疡的临床试验。此次演讲将提供其基于成纤维细胞的技术最新进展及其在治疗多种慢性疾病方面的潜在应用。
- None.
- None.
HOUSTON, Sept. 23, 2025 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, today announced that Chief Scientific Officer, Hamid Khoja, Ph.D., will present at the 2025 Cell & Gene Meeting on the Mesa Conference taking place October 6-8 in Phoenix, Arizona.
“The Cell & Gene Meeting on the Mesa provides an excellent opportunity to share updates on our fibroblast-based technologies and their potential to address unmet needs in several indications,” said Hamid Khoja, Ph.D., Chief Scientific Officer of FibroBiologics. “We look forward to providing continued updates as we advance our pipeline, including the initiation of our clinical trial for diabetic foot ulcers planned for the first quarter of 2026.”
Details of the presentations are as follows:
Event: 2025 Cell & Gene Meeting on the Mesa
Session Date and Time: October 7, 2025, at 2:15 p.m. MST
Location: FLW Ballroom F
For more information, please visit FibroBiologics' website or email FibroBiologics at: info@fibrobiologics.com.
Cautionary Statement Regarding Forward-Looking Statements
This communication contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements include information concerning plans for, and the anticipated timing of the initiation of, FibroBiologics’ clinical trials and research and development programs, and the potential clinical benefits of fibroblasts and fibroblast-derived materials. These forward-looking statements are based on FibroBiologics' management's current expectations, estimates, projections and beliefs, as well as a number of assumptions concerning future events. These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside FibroBiologics' management's control, that could cause actual results to differ materially from the results discussed in the forward-looking statements, including those set forth under the caption "Risk Factors" and elsewhere in FibroBiologics' annual, quarterly and current reports (i.e., Form 10-K, Form 10-Q and Form 8-K) as filed or furnished with the SEC and any subsequent public filings. Copies are available on the SEC's website, www.sec.gov. These risks, uncertainties, assumptions and other important factors include, but are not limited to: (a) risks related to FibroBiologics' liquidity and its ability to maintain capital resources sufficient to conduct its business; (b) expectations regarding the initiation, progress and expected results of our R&D efforts and preclinical studies; (c) the unpredictable relationship between R&D and preclinical results and clinical study results; and (d) the ability of FibroBiologics to successfully prosecute its patent applications. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FibroBiologics assumes no obligation and, except as required by law, does not intend to update, or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. FibroBiologics gives no assurance that it will achieve its expectations.
About FibroBiologics
Based in Houston, FibroBiologics is a clinical-stage biotechnology company developing a pipeline of treatments and seeking potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. FibroBiologics holds 270+ US and internationally issued patents/patents pending across various clinical pathways, including wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, human longevity, and cancer. FibroBiologics represents the next generation of medical advancement in cell therapy and tissue regeneration. For more information, visit www.FibroBiologics.com.
General Inquiries:
info@fibrobiologics.com
Investor Relations:
Nic Johnson
Russo Partners
(212) 845-4242
fibrobiologicsIR@russopr.com
Media Contact:
Liz Phillips
Russo Partners
(347) 956-7697
Elizabeth.phillips@russopartnersllc.com
FAQ
When and where will FibroBiologics (FBLG) present at the 2025 Cell & Gene Meeting on the Mesa?
What is FibroBiologics' (FBLG) upcoming clinical trial plan for 2026?
How many patents does FibroBiologics (FBLG) currently have?
What is FibroBiologics' (FBLG) main focus as a biotechnology company?
